Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass PathwaysCMPS +6.53%33 Equity-to-Asset is 0.17 as of Jun. 2026, which is 79% below its 10-year median of 0.82. GuruFocus rates CMPS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 685 Healthcare Providers & Services companies, Compass Pathways ranks worse than 84.38% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Compass Pathways's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $84.53 Mil. Compass Pathways's Total Assets for the quarter that ended in Jun. 2026 was $504.56 Mil.
The historical rank and industry rank for Compass Pathways's Equity-to-Asset or its related term are showing as below:
CMPS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.94 Med: 0.82 Max: 0.98
Current: 0.17
During the past 8 years, the highest Equity to Asset Ratio of Compass Pathways was 0.98. The lowest was -0.94. And the median was 0.82.
CMPS's Equity-to-Asset is ranked worse than 84.38% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs CMPS: 0.17
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Compass Pathways Equity-to-Asset Related Terms
Compass Pathways Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Compass Pathways's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMPS vs ARDT, HCSG, INNV: Equity-to-Asset Comparison
For the Medical Care Facilities subindustry, Compass Pathways's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Compass Pathways's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (CMPS) has a Equity-to-Asset of 0.17 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Compass Pathways and its competitors. This is 79% below median its historical median of 0.82. According to the industry distribution chart, Compass Pathways ranks #578 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 84.4%.
Is Compass Pathways' Equity-to-Asset too high?
Compass Pathways' current Equity-to-Asset of 0.17 is 79% below median its 10-year median of 0.82. The Healthcare Providers & Services industry median Equity-to-Asset is 0.48. Compass Pathways' value of 0.17 is 64.6% below this industry median. Based on the distribution chart, Compass Pathways ranks #578 out of 685 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Compass Pathways has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Equity-to-Asset compare to ARDT and HCSG?
According to the Healthcare Providers & Services industry distribution chart, Compass Pathways ranks #578 out of 685 companies for Equity-to-Asset. This places Compass Pathways in the lower half of its industry. The industry median Equity-to-Asset is 0.48. Compass Pathways' value of 0.17 is 64.6% below this benchmark. While the company's 10-year median is 0.82 vs. the industry median of 0.48, Compass Pathways has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Pathways's current Equity-to-Asset of 0.17 is 64.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Compass Pathways and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Pathways's current Equity-to-Asset is 0.17, which is 79% below median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (CMPS) has a current Equity-to-Asset of 0.17. The current Equity-to-Asset is 0.17, which is 79% below median its 10-year median of 0.82 and 64.6% below the Healthcare Providers & Services industry median of 0.48. Compass Pathways' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Compass Pathways (CMPS), the current Equity-to-Asset is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
33GF Score
Get the complete analysis for CMPS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPS has been successfully added to your 
